StratumSkin science, cited
Ingredient Index

Dandruff & seborrheic dermatitis · Fungal acne

Ketoconazole

Topical antifungal

Overall grade BTypical strength 2% shampoo or cream3 sources

The best-evidenced antifungal on this page, but for one specific job: dandruff and seborrheic dermatitis. A Cochrane review pooling over 9,000 people found a real, if modest, benefit over placebo. Using it as a body wash for 'fungal acne' (a real condition, properly called Malassezia folliculitis) is common dermatologist advice. It's built on the same organism and the same drug class, not on a trial that actually tested this specific use. We think the recommendation is reasonable. We also think 'reasonable extrapolation' and 'proven' are different claims, and we should say which one we're making.

Claim by claim

BDandruff & seborrheic dermatitisCochrane's own review calls the underlying trials 'low-quality evidence' despite a real, significant effect across 51 pooled studies. It's a real benefit, graded down for how it was measured rather than how large it was.
DFungal acne (Malassezia folliculitis on the body)No published trial tests this directly. The recommendation rests on the drug's known activity against the same organism and its dandruff results, not on a fungal-acne trial that exists.
BTolerabilityGenerally well tolerated. Head-to-head trials found similar remission rates to topical steroids, with meaningfully fewer side effects.

References

  1. Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis. Cochrane Database of Systematic Reviews, 2015.BCochrane systematic review, 51 trials, 9,052 participants·Ketoconazole 2% showed roughly a 31% lower risk of failed clearance vs placebo at 4 weeks, rated low-quality evidence by the review's own GRADE assessment. Remission rates were similar to topical steroids, with about 44% fewer side effects.PubMed 25933684DOI 10.1002/14651858.CD008138.pub3
  2. Piérard-Franchimont C, Goffin V, Decroix J, Piérard GE. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacology and Applied Skin Physiology, 2002.COpen-label randomised trial, n=331·Ketoconazole reached 73% improvement vs 67% for zinc pyrithione (p<0.02) over 4 weeks. Open-label, not double-blind, which weakens how much weight this deserves against a placebo-controlled trial.PubMed 12476017DOI 10.1159/000066452
  3. Pari T, et al. Randomised double blind controlled trial of 2% ketoconazole cream versus 0.05% clobetasol 17-butyrate cream in seborrhoeic dermatitis. Journal of the European Academy of Dermatology and Venereology, 1998.CRandomised controlled trial, n=36, conducted in India·A small India-based trial comparing ketoconazole cream against a steroid. Cochrane's own risk-of-bias assessment flagged several domains as unclear, including allocation concealment, compliance and intention-to-treat analysis. Treat it as supporting evidence, not standalone.PubMed 9552768

Your turn

Did this hold up? Tell us honestly — especially if it didn’t.

Anonymous. Stored in your browser.

The Sunday study

One paper a week, explained properly

We pick a single new study, tell you what it measured, how many people it measured it in, and whether it should change anything you're doing — plus the two articles we published that week. No panic, and no hype.

We don't recommend products yet. When we do, they'll be things you can actually buy in India, any affiliate link will be labelled as one, and a commission will never buy a recommendation.

One email each Sunday. Unsubscribe in one click.